Onco TCS: Phase II data; Phase II/III

IEX said interim results from a U.S. Phase II trial showed a 100% overall response rate in 26 NHL patients receiving Onco TCS in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and p...